Dose-dependent apoptotic and necrotic myocyte death induced by the β2-adrenergic receptor agonist, clenbuterol

Muscle and Nerve

Volumn 32, Issue 6, 2005, Pages 767-774

  Burniston, Jatin G ^a   Chester, Neil ^a   Clark, William A ^b   Tan, Lip Bun ^c   Goldspink, David F ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b MICHAEL REESE HOSPITAL   (United States)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

2 adrenergic receptor; Cardiac muscle; Caspase 3; Immunohistochemistry; Muscle hypertrophy; Myocyte death; Secondary necrosis; Skeletal muscle

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CLENBUTEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BETA ADRENERGIC STIMULATION; CELL DEATH; CELL LABELING; CONTROLLED STUDY; CYTOLYSIS; DOSE TIME EFFECT RELATION; LOW DRUG DOSE; MALE; MUSCLE CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM;

ADRENERGIC BETA-AGONISTS; ANIMALS; APOPTOSIS; CASPASE 3; CASPASES; CELL COUNT; CLENBUTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MALE; MUSCLE CELLS; NECROSIS; PRIMIDONE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 26044480160     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20407     Document Type: Article

References (39)

1. Allen TR, Hunter WJ, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharm Toxicol Method 1997;37:215-228.
2. Balazs T, Ferrans VJ. Cardiac lesions induced by chemicals. Environ Health Perspect 1978;26:181-191.
3. Burniston JG, Ng Y, Clark WA, Colyer J, Tan L-B, Goldspink DF. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. J Appl Physiol 2002;93:1824-1832.
4. 2-Adrenergic receptor stimulation in vivo induces apoptosis in the rat heart and soleus muscle. J Appl Physiol 2005;98:1379-1386.
5. Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. Metabolism 1994;43:1119-1125.
6. Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol in skeletal muscle are mediated by beta2-adrenoceptor activation. Am J Physiol Endocrinol Metab 1992;263:E50-E56.
7. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta1- and beta2-adrenergic receptors on cardiac myocyte apoptosis. Circulation 1999;100:1210-1217.
8. Duchanie D. Underground steroid handbook (II) update: 1992. Venice, CA: HLR Technical Books; 1992.
9. Dumount EAWJ, Hofstra L, Van Heerde WL, Vam Den Eijnde S, Doevendans PAF, DeMuinck E, et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model. Circulation 2000;102:1564-1568.
10. Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. Clin Sci 2000;98:339-347.
11. Emery PW, Rothwell NJ, Stock MJ, Winter PD. Chronic effects of beta2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep 1984;4:83-91.
12. Goldspink DF, Burniston JG, Ellison GM, Clark WA, Tan LB. Catecholamine-induced apoptosis and necrosis in cardiac and skeletal myocytes of the rat in vivo: the same or separate death pathways? Exp Physiol 2004;89:407-416.
13. Goldspink DF, Burniston JG, Tan L-B. Cardiomyocyte death and the ageing and failing heart. Exp Physiol 2003;88:447-458.
14. Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS. Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. Am J Physiol Heart Circ Physiol 2005;289:H344-H349.
15. Hinkle RT, Hodge KMB, Cody DB, Sheldon RJ, Kobilka BK, Isfort R. Skeletal muscle hypertrophy and anti-hypertrophic effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve 2002;25:729-734.
16. Honda O, Kuroda M, Joja I, Asaumi J, Takeda Y, Akaki S, et al. Assessment of secondary necrosis of Jurkat cells using a new microscopic system and double staining method with annexin V and propidium iodide. Int J Oncol 2000;16:283-288.
17. Ingalls CP, Barnes WS, Smith SB. Interaction between clenbuterol and run training: effects on exercise performance and MLC isoform content. J Appl Physiol 1996;80:795-801.
18. James TN. The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding it pathogenesis, clinical course, diagnosis and prognosis. Coronary Artery Dis 1998;9:291-307.
19. January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, et al. beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 1997;272:23871-23879.
20. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve 2004;29:120-127.
21. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74:86-107.
22. Kearns CF, McKeever KH. Clenbuterol diminishes aerobic performance in horses. Med Sci Sports Exerc 2002;34:1976-1985.
23. Kerr JFR, Wyllie AH, Currire AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
24. Leist M, Nicotera P. Breakthroughs and views: the shape of cell death. Biochem Biophys Res Commun 1997;236:1-9.
25. Lexell J. Human aging, muscle mass, and fibre type composition. J Gerontol Series A 1995;50A:11-16.
26. Lynch G, Hayes A, Campbell S, Williams D. Effects of beta2-agonist administration and exercise on contractile activation of skeletal muscle fibres. J Appl Physiol 1996;81:1610-1618.
27. Majno G, Joris I. Apoptosis, oncosts, and necrosis: an overview of cell death. Am J Pathol 1995;146:3-15.
28. Maltin CA, Hay SM, Delday MI, Lobley GE, Reeds JP. The action of the beta-agonist clenbuterol on protein metabolism in innervated and denervated phasic muscles. Biochem J 1989;261:965-971.
29. Ng Y, Goldspink DF, Burniston JG, Clark WA, Colyer J, Tan L.-B. Characterisation of isoprenaline myotoxicity on slow-twitch verses cardiac muscle. Int J Cardiol 2002;86:299-309.
30. Raffray M, Cohen GM. Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death? Pharmacol Ther 1997;75:153-177.
31. Sleeper MM, Kearns CF, McKeever KH. Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exerc 2002;34:643-650.
32. Soma LR, Uboh CE, Guan F, Luo Y, Teleis D, Runbo L, et al. Tissue distribution of clenbuterol in the horse. J Vet Pharmacol Therap 2004;27:91-98.
33. Tan L-B, Burniston JG, Clark WA, Ng Y, Goldspink DF. Characterisation of adrenoceptor involvement in skeletal and cardiac myotoxicity induced by sympathomimetic agents: towards a new bioassay for beta-blockers. J Cardiovasc Pharmacol 2003;41:518-525.
34. 2-adrenocecptor-mediated control mechanism in the pithed rat. Naunyn-Schmiedebergs Arch Pharmacol 1994;349:570-577.
35. Van Den Eijnde SM, Boshart L, Reutelingsperger CPM, De Zeetiw CI, Vermeij-Keers C. Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis. Cell Death Diff 1997;4:311-316.
36. Von Deutsch DA, Abukhalaf IK, Wineski LE, Aboul-Enein HY, Pitts SA, Parks BA, et al. Beta-agonist-induced alterations in organ weights and protein content: comparison of racemic clenbuterol and its enantiomers. Chirality 2000;12:637-648.
37. Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Clenbuterol induces cardiac hypertrophy with normal functional, morphological and molecular features. Cardiovasc Res 1998;37:115-122.
38. Xiao R-P, Zhu WZ, Zheng M, Chakir K, Bond RA, Lakatta EG, et al. Subtype-specific beta-adrenergic signalling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 2004;25:358-365.
39. Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat and rabbit. J Pharmacobiodyn 1985;8:385-391.